Indacaterol/glycopyrronium bromide/mometasone
Indacaterol/glycopyrronium bromide/mometasone, sold under the brand name Enerzair Breezhaler among others, is an inhalable fixed-dose combination medication for the treatment of asthma. It contains indacaterol as acetate, glycopyrronium bromide, and mometasone furoate.

The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat). Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.

It is the first asthma triple-combination therapy; it consists of a fixed-dose combination of three active substances (indacaterol, glycopyrronium bromide and mometasone furoate) in capsules, to be administered using an inhaler. An optional electronic sensor may also be co-packed with the product. The sensor will be attached to the base of the inhaler to collect data on the use of the inhaler by the patient. The sensor will send the data to an app on a smart phone or other suitable device. It was approved for medical use in the European Union in July 2020. 
Q1779868
combination medication
Concept
Q425654
indacaterol
Concept
Q27162963
glycopyrronium bromide
Concept
Q1044248
mometasone furoate
Concept
Q97628024
Indacaterol/glycopyrronium bromide/mometasone
Concept
2020-07-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
July 2020
DATE
instance of